<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of dystonia in children and adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of dystonia in children and adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of dystonia in children and adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andres Deik, MD, MSEd
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cynthia Comella, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of dystonia is primarily symptomatic, although some causes of dystonia are amenable to specific therapies. No curative therapies are available. Management options include oral medications, botulinum toxin (BoNT) injections, and deep brain stimulation (DBS).
        </p>
        <p>
         This topic will review the treatment of dystonia. Other clinical aspects of dystonia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia"
         </a>
         .)
        </p>
        <p>
         Clinical features, diagnosis, and treatment of tardive dyskinesia, including tardive dystonia, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4908.html" rel="external">
          "Tardive dyskinesia: Prevention, treatment, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3981161942">
         <span class="h1">
          CHILDREN AND ADOLESCENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most dystonia presenting in childhood is genetic or idiopathic, either isolated or in combination with other movement disorders. In a small but important subset of patients, dystonia is exquisitely sensitive to levodopa. In the remaining patients, the therapeutic window of symptomatic medications is narrow, and side effects often limit clinical benefit  (
         <a class="graphic graphic_algorithm graphicRef130110" href="/z/d/graphic/130110.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef75422" href="/z/d/graphic/75422.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Early-onset isolated dystonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1780989238">
         <span class="h2">
          Levodopa trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with isolated, idiopathic focal or generalized dystonia, an initial trial of
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         is indicated to identify those with dopa-responsive dystonia (DRD). Although relatively rare, DRD represents a treatable dystonia syndrome, and levodopa is the treatment of choice. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dopa-responsive dystonia'
         </a>
         .)
        </p>
        <p>
         Levodopa is always given in combination with a peripheral decarboxylase inhibitor (eg,
         <a class="drug drug_general" data-topicid="9200" href="/z/d/drug information/9200.html" rel="external">
          carbidopa
         </a>
         or benserazide). In the United States, the combination of
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         is used; outside the United States, benserazide-levodopa may also be available. A treatment trial should be initiated with low doses of levodopa, such as carbidopa-levodopa 25/100 mg, one-half to one tablet daily, irrespective of age. Once started without side effects, the total daily levodopa dose can be increased as tolerated by 50 to 100 mg daily every week up to a full tablet of 25/100 mg three times daily, or more.
        </p>
        <p>
         The usual practice is to titrate to the lowest levodopa dose that produces a useful clinical response. Children whose dystonia fails to improve by 600 mg daily seldom find relief at higher doses, and complete lack of improvement at 1000 mg daily should prompt discontinuation of this medication.
        </p>
        <p>
         Patients with a clinically significant positive response (ie, those with DRD) should continue levodopa indefinitely. The dose can be adjusted over time to obtain the optimum response.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          Carbidopa-levodopa
         </a>
         is dramatically beneficial in patients with DRD. Often, small doses of levodopa (50 to 100 mg) one to three times daily can virtually eliminate the dystonic symptoms of DRD for an indefinite period of time without causing motor complications [
         <a href="#rid1">
          1-3
         </a>
         ]. A sustained and complete response occurs with variable doses ranging from 100 to 750 mg daily [
         <a href="#rid1">
          1,4
         </a>
         ]. One case series of 20 patients reported that the mean daily levodopa doses for clinical benefit in patients with and without associated dyskinesia were 343 and 189 mg, respectively [
         <a href="#rid3">
          3
         </a>
         ]. Of note, whereas levodopa-induced dyskinesias are not typical in patients with DRD, unusual, long-lasting dyskinesias have been reported in Korean families with novel GTP cyclohydrolase 1 (
         <em>
          GCH1
         </em>
         ) mutations [
         <a href="#rid5">
          5
         </a>
         ]. The evaluation and genetic testing of patients with DRD is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dopa-responsive dystonia'
         </a>
         .)
        </p>
        <p>
         In other forms of dystonia, the response rate with
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         is approximately 15 percent [
         <a href="#rid6">
          6
         </a>
         ]. The degree of improvement among these patients is highly variable, and genetic testing can be pursued to exclude DRD whenever clinically relevant. Carbidopa-levodopa is mostly used as an adjunct in patients without DRD who find it beneficial [
         <a href="#rid7">
          7
         </a>
         ]. It is often worth tapering off carbidopa-levodopa completely first to be sure that it is offering meaningful benefit before continuing it long term. This helps to avoid exposing patients to long-term side effects for marginal or no benefit.
        </p>
        <p class="headingAnchor" id="H2737655213">
         <span class="h2">
          Early-onset generalized isolated dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children and adolescents with isolated generalized dystonia that does not respond to a trial of levodopa, anticholinergic drug therapy is an appropriate first-line strategy in most patients  (
         <a class="graphic graphic_algorithm graphicRef130110" href="/z/d/graphic/130110.html" rel="external">
          algorithm 1
         </a>
         ). High
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         doses may be necessary to achieve a clinically significant response in children. Second-line symptomatic therapies include
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and benzodiazepines.
        </p>
        <p class="headingAnchor" id="H3691784210">
         <span class="h3">
          Anticholinergic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of action of anticholinergic therapy in dystonia is not well understood.
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          Trihexyphenidyl
         </a>
         is a nonselective muscarinic receptor antagonist, which in animal models of DYT-TOR1A dystonia increases striatal dopamine release and efflux [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Although there is substantial clinical experience and agreement on the role of anticholinergic therapy in children with dystonia, supporting evidence is relatively limited [
         <a href="#rid4">
          4,9-12
         </a>
         ]. In one of the few controlled trials, high-dose
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         (titrated in weekly increments of 5 mg daily up to 30 mg daily, in four divided doses) resulted in a clinically significant response in 71 percent of 31 children and young adults with mostly early-onset isolated dystonia [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1488209801">
         <span class="h4">
          Trihexyphenidyl
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          Trihexyphenidyl
         </a>
         is the most commonly used anticholinergic drug for dystonia. In children and young adults, a typical starting dose is 2 mg twice daily. The dose is titrated gradually upwards in weekly increments of 2 to 5 mg per day as needed to achieve benefit; the rate of titration should be slowed if side effects occur. The maximum dose of trihexyphenidyl may be as high as 100 mg daily given in three to four divided doses [
         <a href="#rid11">
          11
         </a>
         ]. Benefit may be delayed for several weeks. However, children and adolescents who do not experience response at 20 to 30 mg/day rarely exhibit meaningful symptomatic improvements at higher doses.
        </p>
        <p>
         Discontinuation of anticholinergic agents should be gradual, as withdrawal effects may occur.
        </p>
        <p>
         Anticholinergic side effects include dry mouth, blurred vision, constipation, urinary hesitancy or retention, tachycardia, pupil dilatation, and increased intraocular pressure. Dry mouth may increase the occurrence of dental caries.
        </p>
        <p>
         Additional side effects of
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         include dizziness, confusion, memory impairment, nausea, vomiting, and anxiety. The central side effects, including memory loss and sedation, are dose limiting and can interfere with school and other activities. Cognitive side effects may become more apparent as the child ages into adulthood and the high doses are no longer tolerated.
        </p>
        <p class="headingAnchor" id="H170618945">
         <span class="h4">
          Other anticholinergic drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other anticholinergic agents, including
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         , and those with both anticholinergic and antihistaminergic effects (eg,
         <a class="drug drug_general" data-topicid="15559" href="/z/d/drug information/15559.html" rel="external">
          procyclidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ) have also been used anecdotally for dystonia. For each of these agents, a similar slow titration to benefit or side effects is recommended.
        </p>
        <p class="headingAnchor" id="H2000610479">
         <span class="h3">
          Second-line medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who do not respond to or tolerate anticholinergic therapy, options include high-dose
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and benzodiazepines  (
         <a class="graphic graphic_algorithm graphicRef130110" href="/z/d/graphic/130110.html" rel="external">
          algorithm 1
         </a>
         ). Whereas benzodiazepines may provide a more robust antidystonic effect than baclofen, sedation and the potential for tolerance and abuse are considerations when prescribing a benzodiazepine.
        </p>
        <p class="headingAnchor" id="H3399766171">
         <span class="h4">
          High-dose baclofen
         </span>
         <span class="headingEndMark">
          —
         </span>
         One review found retrospective evidence that high-dose oral
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         (40 to 180 mg daily) was associated with improvement in approximately 30 percent of children and adolescents (n = 31) with idiopathic generalized dystonia [
         <a href="#rid13">
          13
         </a>
         ]. Side effects of oral baclofen, including nausea and sedation, may be intolerable. The sudden withdrawal of baclofen can cause serious side effects, including seizures.
        </p>
        <p class="headingAnchor" id="H2044089300">
         <span class="h4">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         is a frequently used benzodiazepine in the pediatric dystonia population. A typical starting dose in older children is half of a 0.5 mg tablet at bedtime. The drug can be titrated slowly (every fourth day, or longer) as tolerated, until the desired response occurs. The usual maintenance dose of clonazepam is 1 to 3 mg daily given in three divided doses. For children under 10 years of age, a starting dose of 0.01 mg/kg per day is recommended. The usual maintenance dose is 0.1 to 0.2 mg/kg daily given in three divided doses [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Rapid discontinuation may lead to withdrawal symptoms. Therefore, if treatment is not effective or side effects arise, the dose should be slowly tapered.
        </p>
        <p class="headingAnchor" id="H3467916058">
         <span class="h3">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with generalized dystonia that is refractory to oral medications or who have a particularly problematic area may benefit from botulinum toxin (BoNT). However, it is not reasonable to use widespread BoNT injection treatment for all symptoms of generalized dystonia because of dose limitations. (See
         <a class="local">
          'Botulinum toxin injections'
         </a>
         below.)
        </p>
        <p>
         Children with debilitating, early-onset isolated generalized dystonia who do not respond to or tolerate oral medications or BoNT may be candidates for deep brain stimulation (DBS). (See
         <a class="local">
          'Deep brain stimulation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2766711566">
         <span class="h2">
          Pediatric dystonic storm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dystonic storm is an infrequent medical emergency that requires early recognition and aggressive, multimodal treatment to minimize morbidity and mortality. The mortality of dystonic storm has been reported to exceed 10 percent in some series [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         In a retrospective, hospital-based study of 23 children hospitalized with dystonic storm, patients required multiple oral medications (including anticholinergics, benzodiazepines, levodopa, and
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         , among others), intravenous
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         infusion, and, in some cases, mechanical ventilation, to achieve symptom control [
         <a href="#rid15">
          15
         </a>
         ]. The successful use of emergency deep brain stimulation has been reported in the most refractory cases. Management is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">
          "Hyperkinetic movement disorders in children", section on 'Status dystonicus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3132809416">
         <span class="h2">
          Focal dystonia in children
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with isolated cervical dystonia or other types of isolated focal dystonia, BoNT injections are considered first-line therapy, as in adults  (
         <a class="graphic graphic_algorithm graphicRef130110" href="/z/d/graphic/130110.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Botulinum toxin injections'
         </a>
         below.)
        </p>
        <p>
         If BoNT injections are not tolerated or injections are not feasible, oral medications can be tried. We typically use an anticholinergic drug such as
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         or
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         first. For those who do not respond to or tolerate anticholinergic therapy, benzodiazepines or
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         can also be tried. (See
         <a class="local">
          'Anticholinergic therapy'
         </a>
         above and
         <a class="local">
          'Second-line medications'
         </a>
         above.)
        </p>
        <p>
         We suggest bilateral DBS of the internal globus pallidus (GPi) for children with debilitating isolated cervical dystonia or other types of isolated focal dystonia who do not respond to or tolerate BoNT treatment or oral pharmacologic therapy, including levodopa. (See
         <a class="local">
          'Surgical therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1100450056">
         <span class="h1">
          ADULTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most dystonia presenting in adulthood is isolated and either focal or segmental. Cervical dystonia is the most common isolated dystonia in adults, and botulinum toxin (BoNT) injections are the preferred approach  (
         <a class="graphic graphic_algorithm graphicRef130112" href="/z/d/graphic/130112.html" rel="external">
          algorithm 2
         </a>
         ). Oral medications and deep brain stimulation (DBS) play a secondary role for refractory disease and for adults with generalized dystonia.
        </p>
        <p class="headingAnchor" id="H2365326893">
         <span class="h2">
          Role of levodopa trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         A levodopa trial is suggested for certain adults with isolated, idiopathic focal or generalized dystonia, since adult onset, although atypical, is part of the phenotype of dopa-responsive dystonia (DRD), and some adults may respond favorably. In particular, a levodopa trial is appropriate in patients with a family history of DRD or parkinsonism and for those in whom the dystonia may have been present since childhood or adolescence. Dosing is reviewed above. (See
         <a class="local">
          'Levodopa trial'
         </a>
         above.)
        </p>
        <p>
         DRD is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4886.html" rel="external">
          "Etiology, clinical features, and diagnostic evaluation of dystonia", section on 'Dopa-responsive dystonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1445116190">
         <span class="h2">
          Focal dystonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         BoNT injection therapy is the treatment of choice for adults with cervical dystonia as well as other forms of focal dystonia  (
         <a class="graphic graphic_algorithm graphicRef130112" href="/z/d/graphic/130112.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
         Treatment of cervical dystonia is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/132652.html" rel="external">
          "Cervical dystonia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3902994432">
         <span class="h3">
          Botulinum toxin injections
         </span>
         <span class="headingEndMark">
          —
         </span>
         BoNT is a potent neurotoxin produced by
         <em>
          Clostridium botulinum
         </em>
         that causes regional muscle weakness through its action as a zinc endopeptidase that cleaves specific proteins involved in vesicular fusion. Disruption of these fusion proteins interferes with the release of acetylcholine at the neuromuscular junction, resulting in localized muscle weakness.
        </p>
        <p class="headingAnchor" id="H423079537">
         <span class="h4">
          Dosing and side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, three different forms of BoNT type A (BoNT-A) are marketed, which are designated
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         (Dysport),
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         (Xeomin), and
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         (Botox). Type B BoNT (BoNT-B) is designated
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         (Myobloc). Each of these products is a unique drug with regard to formulation, potency, and dosing [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         There is no unique dose ratio to permit switching among the available BoNT products [
         <a href="#rid17">
          17
         </a>
         ]. However, clinical trial experience suggests that treatment can be switched between
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         and
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         using a 1:1 to 1:1.5 conversion ratio [
         <a href="#rid18">
          18
         </a>
         ]. There is little evidence to support the use of one brand over another, and rotating brands or serotypes is not recommended.
        </p>
        <p>
         There is no consensus regarding standard practices for BoNT injections, including dilution ratios for the different BoNT products, the dose per injection, the total dose per muscle, the number of injections at each site, or the methods of targeting injections (eg, whether guided by vision and palpation, electromyography, electrical stimulation, or ultrasound) [
         <a href="#rid16">
          16
         </a>
         ]. All of these parameters vary among practitioners and centers.
        </p>
        <p>
         Side effects with BoNT treatment are frequent, but typically mild and transient. In the systematic reviews of BoNT for cervical dystonia, adverse events that were significantly more frequent with BoNT-A compared with placebo injections were diffuse weakness/tiredness and dysphagia; other adverse events included neck weakness, dry mouth/sore throat, and voice changes/hoarseness [
         <a href="#rid19">
          19
         </a>
         ]. Adverse events associated with BoNT-B treatment included dysphagia and dry mouth [
         <a href="#rid20">
          20
         </a>
         ]. These side effects are clearly related to the mechanism of action of BoNT. They are attributable to excessive weakness in injected muscles or to diffusion of toxin into nearby structures. In order to effectively use BoNT for any form of dystonia, it is crucial that the injector has knowledge of the functional anatomy of the area involved in order to inject the appropriate muscle, and to avoid nearby structures, such as the apex of the lung, carotid artery, or brachial plexus in the case of cervical dystonia.
        </p>
        <p class="headingAnchor" id="H1351067747">
         <span class="h4">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both BoNT-A and BoNT-B are more effective than placebo or oral anticholinergic therapy for the treatment of cervical dystonia [
         <a href="#rid19">
          19-22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/132652.html" rel="external">
          "Cervical dystonia: Treatment and prognosis", section on 'Efficacy'
         </a>
         .)
        </p>
        <p>
         BoNT is the preferred first-line therapy for other types of focal dystonia as well, including blepharospasm, focal upper limb dystonia (eg, writer's cramp), and adductor laryngeal dystonia (ie, adductor spasmodic dysphonia) [
         <a href="#rid23">
          23-25
         </a>
         ]. Abductor spasmodic dysphonia (ie, abductor laryngeal dystonia) responds less predictably [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blepharospasm
         </strong>
         – A systematic review by the American Academy of Ophthalmology identified two placebo-controlled randomized trials (n = 194) and four blinded comparative trials (n = 719) of different types of BoNT-A for blepharospasm in adults [
         <a href="#rid26">
          26
         </a>
         ]. The review concluded that periocular BoNT-A injections are more effective than placebo for reducing blepharospasm severity based on standardized rating scales and that the three types of BoNT-A (
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         ) have similar efficacy. In the largest placebo-controlled trial, patients treated with incobotulinumtoxinA improved by 0.8 points on a 4-point severity scale from a baseline score of 3.1 (adjusted mean difference compared with placebo 1.0 points, 95% CI 0.5-1.4) [
         <a href="#rid27">
          27
         </a>
         ]. The most common adverse effects of injections were eyelid ptosis (19 versus 6 percent in placebo group), dry eye (19 versus 12 percent), and dry mouth (15 versus 3 percent). Lower-quality data suggest that pretarsal injections are associated with higher response rates than preseptal injections  (
         <a class="graphic graphic_figure graphicRef119381" href="/z/d/graphic/119381.html" rel="external">
          figure 1
         </a>
         ), and that efficacy can be maintained with repeated injections for at least 10 years [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Focal upper limb dystonia
         </strong>
         – A trial randomly assigned 40 patients with writer's cramp to treatment with either BoNT-A or placebo injections [
         <a href="#rid28">
          28
         </a>
         ]. At 12 weeks, the proportion of patients who reported a beneficial effect and chose to continue treatment (the primary outcome measure) was significantly greater in the BoNT-A group than the placebo group (70 versus 32 percent). In addition, improvement on most, but not all, of the clinical rating scales favored BoNT-A treatment. Transient hand weakness, generally mild, was a side effect of BoNT-A in 75 percent. BoNT has also been used to treat dystonic tremor associated with upper limb dystonia [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spasmodic dysphonia
         </strong>
         – In a double-blind trial involving 13 patients with adductor-type laryngeal dystonia, seven patients were treated with BoNT-A and six received
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. There was significant benefit for several outcomes in the BoNT-A group, including quantitative measures of voice function and subjective patient ratings. Likewise, a meta-analysis published in 2019 suggests BoNT injections improved voice-related quality of life in patients with adductor spasmodic dysphonia [
         <a href="#rid31">
          31
         </a>
         ]. Most patients with spasmodic dysphonia may require smaller BoNT doses over time [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a trial of 15 patients with abductor spasmodic dysphonia that compared different injection techniques of BoNT-A into the posterior cricoarytenoid muscle, improvement with BoNT-A injections was reported by 11 patients [
         <a href="#rid33">
          33
         </a>
         ]. However, blinded assessment by speech pathologists found no statistically significant objective benefit with either BoNT-A injection technique. In addition, there were no differences between techniques.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2080788989">
         <span class="h4">
          Loss of clinical response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with dystonia continue to respond to long-term treatment with BoNT [
         <a href="#rid34">
          34
         </a>
         ]. However, the absence or loss of treatment response to BoNT can occur for a variety of reasons, including inadequate dose, inappropriate muscle selection, concurrent drug therapy, or a change in disease state [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Several observational studies of the long-term effect of BoNT demonstrate continued efficacy over at least 1 year and up to 10 years [
         <a href="#rid36">
          36-38
         </a>
         ]. However, for those patients who experience suboptimal benefits from BoNT therapy, one small randomized clinical trial suggests that physical therapy can be considered as adjunct treatment [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3884423903">
         <span class="h4">
          Neutralizing antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against BoNT (referred to as "neutralizing antibodies") can be detected in a proportion of patients treated with BoNT. However, the clinical significance of such antibodies is not clear, and data on the correlation between antibodies and clinical response are mixed [
         <a href="#rid35">
          35,40,41
         </a>
         ]. Therefore, we do not routinely measure antibodies. A clinical test, such as a unilateral brow injection, is a better test of unresponsiveness and may be used to determine the clinical significance of antibodies, if necessary.
        </p>
        <p>
         Neutralizing antibodies have been reported in association with nearly all BoNT formulations, with a prevalence of approximately 10 to 15 percent among patients treated chronically with BoNT-A [
         <a href="#rid42">
          42
         </a>
         ] and as high as 42 percent among patients treated with BoNT-B [
         <a href="#rid41">
          41
         </a>
         ].
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          IncobotulinumtoxinA
         </a>
         , which does not contain any complexing proteins, has been associated with the lowest rate of neutralizing antibody formation (0.5 percent) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         At least one study has suggested that neutralizing antibodies can be clinically relevant in patients with cervical dystonia [
         <a href="#rid44">
          44
         </a>
         ]. The antibodies were correlated with worse head position and pain, and the need for higher doses of BoNT-A when compared with patients without the antibodies.
        </p>
        <p class="headingAnchor" id="H1351837941">
         <span class="h3">
          Second-line therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with focal dystonia continue to respond to long-term treatment with BoNT [
         <a href="#rid34">
          34
         </a>
         ]. For those who fail to respond or who do not tolerate injection therapy, oral medications can be tried, although the therapeutic window is narrow, and side effects are often dose limiting.
        </p>
        <p>
         We generally use
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         as a first-line therapy in most adults and consider anticholinergic drugs, vesicular monoamine transporter type 2 (VMAT2) inhibitors, and
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         to be second-line options  (
         <a class="graphic graphic_algorithm graphicRef130112" href="/z/d/graphic/130112.html" rel="external">
          algorithm 2
         </a>
         ). Dosing and administration in adults are reviewed below. (See
         <a class="local">
          'Oral medications'
         </a>
         below.)
        </p>
        <p>
         Adults with debilitating isolated cervical dystonia who do not respond to or tolerate BoNT or oral medications should be referred to a multidisciplinary movement disorder clinic for discussion of surgical options such as bilateral DBS of the internal globus pallidus (GPi). (See
         <a class="local">
          'Surgical therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1440027601">
         <span class="h2">
          Generalized dystonia in adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic oral medication trials play a role in adults with generalized dystonia and those with focal dystonias who do not have access to BoNT therapy. For medication-refractory generalized dystonia, surgical therapy is beneficial in appropriate candidates.
        </p>
        <p class="headingAnchor" id="H1966546365">
         <span class="h3">
          Oral medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally use
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         as a first-line oral medication for dystonia in adults, since
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         and other anticholinergic drugs tend not to be as well tolerated in adults compared with children  (
         <a class="graphic graphic_algorithm graphicRef130112" href="/z/d/graphic/130112.html" rel="external">
          algorithm 2
         </a>
         ). Low doses of trihexyphenidyl or
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         are reasonable to try as an alternative second-line therapy. A VMAT2 inhibitor such as
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         may be beneficial for adults with debilitating generalized isolated dystonia, although careful monitoring for side effects, including depression, is necessary.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonazepam
         </strong>
         –
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         may be particularly beneficial for patients who note worsening of dystonia with stress and anxiety, although this has not been studied formally. In uncontrolled studies, clonazepam improves symptoms of dystonia in approximately 20 percent of patients at doses ranging from 1.5 to 12 mg per day [
         <a href="#rid6">
          6
         </a>
         ]. In a review of 206 patients with dystonia receiving oral treatment, clonazepam was associated with the most favorable response rate (40 percent), followed by
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         (20 percent) and
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         (20 percent) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A reasonable starting dose of
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         for dystonia in most adults is 0.5 mg once a day, given before bedtime. The dose may be slowly increased in 0.5 mg increments every week, with daytime dosing added once it is clear that the evening dose is tolerated. Daily doses above 0.5 to 1 mg are typically divided twice or three times daily. Adverse effects from clonazepam include sedation, depression, confusion, and dependence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         should not be stopped abruptly due to risk of withdrawal symptoms. When possible, the dose should be tapered slowly over the course of weeks to months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticholinergic drugs
         </strong>
         – For adults, the typical starting dose of
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         is 1 mg twice daily. The dose can be gradually increased in 2 mg increments at intervals of three to seven days until sufficient improvement or unacceptable side effects occur. Full benefit from gradual dose escalation may be delayed for several weeks or months [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The drug label suggests a maximum total daily dose (given in three or four divided doses) of 15 mg daily for adults and 6 to 10 mg daily for older adults. However, some patients with dystonia may tolerate a higher dose if needed to control symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Narrow-angle glaucoma, confusion, and dementia are contraindications to the use of
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         in adults. Trihexyphenidyl should be used with caution in people over 60 years of age and in patients with benign prostatic hypertrophy or obstructive gastrointestinal disorders. Other side effects are reviewed above. (See
         <a class="local">
          'Trihexyphenidyl'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Supporting evidence for
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         in adults with dystonia is scant [
         <a href="#rid4">
          4,46
         </a>
         ]. A trial of nine adult patients with cranial dystonia found no benefit for trihexyphenidyl or a peripheral anticholinergic agent compared with placebo [
         <a href="#rid12">
          12
         </a>
         ]. A separate open-label study reported that anticholinergic treatment for dystonia was effective in a greater proportion of children than adults, probably because children were able to tolerate higher doses [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VMAT2 inhibitors
         </strong>
         –
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          Tetrabenazine
         </a>
         is a VMAT2 inhibitor and combines monoaminergic depletion and dopamine antagonist effects. Evidence from small trials and case series suggests that tetrabenazine is beneficial in a variety of hyperkinetic movement disorders, including dystonia [
         <a href="#rid45">
          45,47-50
         </a>
         ]. However, it is seldom used for the treatment of dystonia because of the adverse effect profile.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When used,
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         is initiated with 12.5 mg daily for one week and increased by 12.5 mg increments every week, according to clinical response and as tolerated, to a level of 75 to 150 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Side effects of
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         are frequent and include sedation, parkinsonism, depression, akathisia, nervousness, orthostatic hypotension, and insomnia. Patients should be warned specifically that severe depression can occur and that they should notify their clinician if signs or symptoms of depression or suicidality develop.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tardive dyskinesia has not been associated with
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         , probably because its site of action is the presynaptic nerve terminal. It has no dopamine receptor blocking properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The safety, tolerability, and efficacy of the newer VMAT2 inhibitor
         <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">
          deutetrabenazine
         </a>
         is being evaluated for its use in isolated, non-dopa-responsive dystonia. Similarly, there is an ongoing clinical trial of
         <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">
          valbenazine
         </a>
         for the treatment of cervical dystonia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baclofen
         </strong>
         – Patients who are unable to tolerate the sedative effect of
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         , or who have coexisting spasticity, can consider a trial of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         . In adults, baclofen is usually started at 10 mg at night and increased by 5 to 10 mg daily every three to four days as tolerated up to a usual maximum total daily dose of 80 mg/day, divided in three doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         appears to be less effective in adults compared with children. In a review that included 60 adults with focal cranial dystonia, sustained benefit was observed in 18 percent [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Several other medications are under investigation for dystonia but are not routinely used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          Zolpidem
         </a>
         has been reported to improve dystonia in patients with blepharospasm, Meige syndrome, myoclonus dystonia, DYT6, and X-linked dystonia-parkinsonism in small series and single cases [
         <a href="#rid51">
          51-55
         </a>
         ]. A 2019 literature review highlighted the need for randomized trials and long-term follow-up to define the role of this agent in the treatment of dystonia [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8817" href="/z/d/drug information/8817.html" rel="external">
          Sodium oxybate
         </a>
         treatment was associated with improved voice symptoms in a small open-label study of patients with spasmodic dysphonia [
         <a href="#rid57">
          57
         </a>
         ]. Sodium oxybate may act upon abnormal neural activity within the dystonic network (in particular, it may attenuate hyperfunctional activity of cerebellar, thalamic, and primary/secondary sensorimotor cortical regions) [
         <a href="#rid58">
          58
         </a>
         ]. It remains to be demonstrated whether other dystonic disorders that are responsive to ethanol (like myoclonus dystonia) would respond to sodium oxybate as well [
         <a href="#rid59">
          59
         </a>
         ]. Sodium oxybate is a controlled substance, and the side effect profile can be limiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dopamine receptor blockers such as
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         can be beneficial in some patients with dystonia [
         <a href="#rid60">
          60,61
         </a>
         ]. However, this class of medications is not recommended for the treatment of dystonia because of the associated risk of tardive dyskinesia, a disorder that may be disabling and irreversible. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3844108118">
         <span class="h3">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with generalized dystonia, BoNT injections of selected areas that are the most troublesome may be beneficial [
         <a href="#rid62">
          62
         </a>
         ]. However, it is not reasonable to use widespread BoNT injection treatment for all symptoms of generalized dystonia because of dose limitations. (See
         <a class="local">
          'Botulinum toxin injections'
         </a>
         above.)
        </p>
        <p>
         We suggest bilateral DBS of the GPi for adults with debilitating generalized isolated dystonia who do not respond to or tolerate pharmacologic therapy or BoNT, and who are appropriate candidates for the procedure. (See
         <a class="local">
          'Deep brain stimulation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2695097591">
         <span class="h1">
          SURGICAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical treatment is reserved for patients with dystonia who fail treatment with pharmacologic agents and botulinum toxin (BoNT) injections. The mainstay of surgical treatment is microelectrode deep brain stimulation (DBS) of the internal segment of the globus pallidus.
        </p>
        <p>
         Intrathecal
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         is sometimes used in patients with dystonia and elements of spasticity, but it tends not to be effective in patients with only dystonia. (See
         <a class="medical medical_review" href="/z/d/html/118855.html" rel="external">
          "Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues", section on 'Intrathecal baclofen'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H935640634">
         <span class="h2">
          Deep brain stimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among surgical therapies, DBS of the internal globus pallidus (GPi) has emerged as the treatment of choice for children and adults with disabling isolated generalized or cervical dystonia who do not respond to pharmacologic therapy or chemodenervation with BoNT [
         <a href="#rid63">
          63-72
         </a>
         ]. Although it is technically possible to implant younger children, most centers in the United States will consider DBS for children aged five years and above.
        </p>
        <p>
         One of the larger controlled trials of DBS randomly assigned 40 patients (18 to 75 years old) with segmental or generalized isolated dystonia to either GPi stimulation or sham stimulation [
         <a href="#rid73">
          73
         </a>
         ]. Two investigators, who were blind to both group assignment and to chronologic order of the examinations, assessed the severity of dystonia by reviewing videotaped sessions of patients made at baseline and after treatment. The primary endpoint was the change from baseline in the movement subscore on the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). The following observations were reported:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At three months, improvement in the severity of symptoms on the BFMDRS movement subscore was significantly greater in the GPi stimulation group than in the sham stimulation group (-15.8 versus -1.4 points). DBS was significantly more effective than sham stimulation for reduction in disability and improvement in the physical aspects of quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the GPi stimulation group, a positive response to treatment (ie, a &gt;25 percent reduction in the BFMDRS movement subscore) at three months was observed in 15 patients (75 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During a six-month open-label extension period, patients originally assigned to sham stimulation had a similar benefit when switched to active treatment. In addition, improvement was sustained among patients originally assigned to GPi stimulation. During the extension phase, dysarthria (n = 5) and infection at the stimulator site (n = 4) were the most frequent adverse events. There was one lead dislodgement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A longer open-label extension study included 38 patients from the parent trial, all on active stimulation, and reported significant improvement in dystonia at three to five years compared with baseline [
         <a href="#rid74">
          74
         </a>
         ]. There were 21 serious adverse events, mostly related to the device, and one attempted suicide.
        </p>
        <p>
        </p>
        <p>
         Other long-term data regarding the utility of DBS for dystonia are limited [
         <a href="#rid67">
          67,75-78
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One prospective study of 22 patients with generalized isolated dystonia found a clinically significant improvement in motor symptoms and a mild improvement in quality of life three years after bilateral DBS of the GPi [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An observational study of 26 patients with DYT-TOR1A dystonia who had DBS and were followed for mean of 6 years (range 3 to 10 years) found that the benefit from DBS persisted in most [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of 12 patients with blepharospasm and Meige syndrome who were followed for up to 78 months (mean 39 months) after DBS found that dystonia severity (assessed by the BFMDRS) was reduced by approximately 53 percent [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Genetic forms of dystonia have been reported to respond differently to DBS [
         <a href="#rid79">
          79
         </a>
         ]. Whereas DYT-TOR1A and DYT-SGCE tend to have excellent, sustained responses, DYT-TAF1 and DYT-THAP1 can have variable responses, and DBS is contraindicated in patients with DYT-ATP1A3 [
         <a href="#rid80">
          80
         </a>
         ]. Positive responses to DBS have also been reported in patients with DYT-GNAL, an adult-onset cranial-cervical dystonia [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Accurate placement of stimulating electrodes in the area of the intercommissural plane provides for optimal outcome in generalized dystonia [
         <a href="#rid82">
          82
         </a>
         ]. Specific locations in the GPi should be targeted for dystonia in specific body regions, reflecting the somatotopic organization of that structure [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         Although not mentioned in the larger prospective trials, several smaller reports have observed the development of bradykinetic movement disorders including micrographia, parkinsonism, and hypokinetic gait in patients with dystonia who were treated with DBS of the GPi [
         <a href="#rid84">
          84-88
         </a>
         ]. In one of the larger studies that retrospectively analyzed 71 such patients who had no gait disorder due to dystonia before treatment, a new gait disorder developed after bilateral DBS in six patients (8 percent) [
         <a href="#rid87">
          87
         </a>
         ]. The gait disorder was reported at three to six months after DBS surgery and was characterized by shuffling steps and difficulty with gait initiation and turning. Freezing of gait developed at higher voltages but resolved within minutes of stopping stimulation. In all cases, electrode misplacement was ruled out as a cause for the gait disorder. Because all six patients otherwise showed benefit, the DBS settings were adjusted to achieve an optimal balance between controlling dystonia and eliciting freezing of gait.
        </p>
        <p>
         Although less well studied than the GPi, the subthalamic nucleus (STN) is a promising alternative target for DBS in patients with isolated dystonia [
         <a href="#rid89">
          89-92
         </a>
         ]. Based on small studies, the long-term benefit from bilateral STN-DBS in adults with either cervical or generalized dystonia may be similar in magnitude and safety to that of GPi-DBS [
         <a href="#rid93">
          93
         </a>
         ]. Whether targets like the globus pallidus externa (GPe) or the ventral oralis (VO) nucleus of the thalamus will have a role in the treatment of dystonia remains to be established [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         DBS has not been consistently effective for the treatment of acquired dystonia, although small case series and case reports indicate improvement in some patients with various types of acquired dystonia [
         <a href="#rid72">
          72,95-100
         </a>
         ]. One series of six patients with pantothenate kinase-associated neurodegeneration reported that GPi stimulation was associated with major improvement in all six [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H951438374">
         <span class="h2">
          Other approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilateral thalamotomy was used in the 1960s and 1970s for generalized dystonia. However, permanent and serious complications from the procedure (hemiparesis, spasticity, ataxia, dysphagia, and dysarthria) were prohibitive. Since the advent of DBS, stereotactic thalamotomy, pallidotomy, and cervical rhizotomy are only occasionally used to treat refractory dystonia.
        </p>
        <p>
         Pallidotomies performed under magnetic resonance imaging (MRI) guidance using high-intensity focused ultrasound (HiFU) are under study for the treatment of dystonia, usually as a unilateral procedure. HiFU thalamotomy has been reported for the treatment of musician's dystonia [
         <a href="#rid101">
          101
         </a>
         ] and focal hand dystonia [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3172896050">
         <span class="h1">
          INVESTIGATIONAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Novel approaches to the treatment of dystonia include gene therapy and transcranial magnetic stimulation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gene therapy
         </strong>
         – The technique of ribonucleic acid interference (RNAi) is a promising avenue of therapy for DYT-TOR1A dystonia [
         <a href="#rid103">
          103
         </a>
         ]. Using this method, it is possible to inhibit gene expression by inhibiting or degrading the targeted messenger RNA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gene silencing mediated by RNAi is particularly relevant to treatment of DYT-TOR1A dystonia, which arises from a single gene mutation and is primarily a disorder of neuronal function rather than neuronal degeneration. In one study, investigators successfully developed viral mediated RNAi and effectively silenced the expression of mutated torsinA [
         <a href="#rid103">
          103
         </a>
         ]. This technique has not yet been applied to humans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transcranial magnetic stimulation
         </strong>
         – Repetitive, low-frequency transcranial magnetic stimulation can enhance intracortical inhibition and has been evaluated for focal hand dystonia [
         <a href="#rid104">
          104
         </a>
         ] and cervical dystonia [
         <a href="#rid105">
          105
         </a>
         ] in small controlled trials, but additional investigations are needed [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1036307757">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119468.html" rel="external">
          "Society guideline links: Dystonia in children and adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7766860">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83332.html" rel="external">
          "Patient education: Dystonia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p>
         <strong>
          Children and adolescents
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levodopa trial
         </strong>
         – For children with idiopathic focal or generalized dystonia, we recommend a trial of levodopa to confirm or exclude the diagnosis of dopa-responsive dystonia (DRD). (See
         <a class="local">
          'Levodopa trial'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic therapy
         </strong>
         – Children with multifocal or generalized isolated dystonia who do not respond to levodopa can be treated with other oral medications  (
         <a class="graphic graphic_table graphicRef75422" href="/z/d/graphic/75422.html" rel="external">
          table 1
         </a>
         ), botulinum toxin (BoNT) injections, or deep brain stimulation (DBS) in refractory cases  (
         <a class="graphic graphic_algorithm graphicRef130110" href="/z/d/graphic/130110.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral medications
         </strong>
         – For most children and adolescents with debilitating generalized isolated dystonia that does not respond to a trial of levodopa, we suggest initial treatment with an anticholinergic drug such as
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Second-line oral therapies include
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and benzodiazepines. (See
         <a class="local">
          'Anticholinergic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Role of BoNT injections
         </strong>
         – For children and adolescents who have debilitating multifocal or generalized isolated dystonia that does not respond to pharmacologic treatment, and for those with focal dystonia, we suggest BoNT injections of selected muscles that are most troublesome (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, widespread injections are not a reasonable option for multifocal or generalized dystonia. (See
         <a class="local">
          'Refractory disease'
         </a>
         above and
         <a class="local">
          'Focal dystonia in children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical options
         </strong>
         – For children with debilitating isolated dystonia who do not respond to pharmacologic therapy or BoNT injections, we suggest referral to a multidisciplinary movement disorders clinic for consideration of bilateral DBS of the internal globus pallidus (GPi). Bilateral DBS of the subthalamic nucleus (STN) is a reasonable alternative in selected cases. (See
         <a class="local">
          'Deep brain stimulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          Adults
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of levodopa trial
         </strong>
         – Although adult onset of DRD is atypical, we suggest a levodopa trial for most adults with idiopathic focal or generalized dystonia. However, there is no consensus regarding a trial of levodopa for adults in this setting. (See
         <a class="local">
          'Role of levodopa trial'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cervical dystonia
         </strong>
         – BoNT injections are the mainstay of therapy for cervical dystonia. Oral medications are used in patients who cannot receive injections and for those with an inadequate response to first-line therapy. (See
         <a class="medical medical_review" href="/z/d/html/132652.html" rel="external">
          "Cervical dystonia: Treatment and prognosis", section on 'Goals and approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other focal dystonias
         </strong>
         – For adults with blepharospasm, focal upper limb dystonia (including writer's cramp), and adductor spasmodic dysphonia (adductor laryngeal dystonia), we recommend BoNT injection therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Focal dystonia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of oral medications
         </strong>
         – Symptomatic medication trials play a role in adults with generalized dystonia and those with focal dystonias who do not have access to BoNT therapy  (
         <a class="graphic graphic_algorithm graphicRef130112" href="/z/d/graphic/130112.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Generalized dystonia in adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most adults with refractory generalized dystonia, we suggest first-line therapy with a benzodiazepine such as
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Low doses of
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         or
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         are alternative second-line therapies. (See
         <a class="local">
          'Oral medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A vesicular monoamine transporter type 2 (VMAT2) inhibitor such as
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         may be beneficial for adults with debilitating generalized isolated dystonia, although careful monitoring for side effects, including depression, is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory dystonia
         </strong>
         – For adults with debilitating generalized dystonia or other types of focal/segmental isolated dystonia who do not respond to oral pharmacologic therapy or BoNT injections, we suggest referral to a multidisciplinary movement disorders clinic for consideration of bilateral DBS of the GPi. (See
         <a class="local">
          'Deep brain stimulation'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rajput AH, Gibb WR, Zhong XH, et al. Dopa-responsive dystonia: Pathological and biochemical observations in a case. Ann Neurol 1994; 35:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutt JG, Nygaard TG. Response to levodopa treatment in dopa-responsive dystonia. Arch Neurol 2001; 58:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang WJ, Calne DB, Tsui JK, de la Fuente-Fernández R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord 2001; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: Report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JY, Yang HJ, Kim JM, Jeon BS. Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia. Parkinsonism Relat Disord 2013; 19:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988; 50:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinson VK, Goetz CG. Torsion Dystonia in Children. Curr Treat Options Neurol 2003; 5:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs AM, Fan X, Donsante C, et al. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol Dis 2019; 125:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 1983; 37:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983; 33:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke RE, Fahn S, Marsden CD. Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutt JG, Hammerstad JP, deGarmo P, Carter J. Cranial dystonia: Double-blind crossover study of anticholinergics. Neurology 1984; 34:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992; 15:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini AG, Hassan I, Sharma K, et al. Status Dystonicus in Children: A Cross-Sectional Study and Review of Literature. J Child Neurol 2022; 37:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goswami JN, Roy S, Patnaik SK. Pediatric Dystonic Storm: A Hospital-Based Study. Neurol Clin Pract 2021; 11:e645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A. Terminology for preparations of botulinum neurotoxins: What a difference a name makes. JAMA 2011; 305:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman MA, Barron R, Tanis DC, et al. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007; 29:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagan FL, Harrison A. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: A new botulinum neurotoxin A. Parkinsonism Relat Disord 2012; 18:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelão M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2017; 12:CD003633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2016; :CD004315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duarte GS, Castelão M, Rodrigues FB, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2016; 10:CD004314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues FB, Duarte GS, Castelão M, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev 2021; 4:CD004312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin 2015; 33:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilyk JR, Yen MT, Bradley EA, et al. Chemodenervation for the treatment of facial dystonia: A report by the American Academy of Ophthalmology. Ophthalmology 2018; 125:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial. Mov Disord 2011; 26:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: A randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007; 78:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajan R, Srivastava AK, Anandapadmanabhan R, et al. Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial. JAMA Neurol 2021; 78:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troung DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991; 101:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faham M, Ahmadi A, Silverman E, et al. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis. J Voice 2021; 35:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French G, Bosch JD, Randall DR. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. J Otolaryngol Head Neck Surg 2020; 49:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bielamowicz S, Squire S, Bidus K, Ludlow CL. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001; 110:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: A systematic review. Neurotox Res 2012; 22:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008; 23:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna) 2013; 120:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 2015; 349:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu W, Rundle-Gonzalez V, Kulkarni SJ, et al. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. Parkinsonism Relat Disord 2019; 63:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing? Clin Neuropharmacol 2009; 32:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinnapongse RB, Lew MF, Ferreira JJ, et al. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: Report of 4 prospective, multicenter trials. Clin Neuropharmacol 2012; 35:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019; 92:e48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing Antibody and Botulinum Toxin Therapy:   A Systematic Review and Meta-analysis. Neurotox Res 2016; 29:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hefter H, Rosenthal D, Bigalke H, Moll M. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Ther Adv Neurol Disord 2019; 12:1756286419892078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo KA, Kim HJ, Yoo D, et al. Patient-reported responses to medical treatment in primary dystonia. J Clin Neurosci 2020; 75:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study. Ann Neurol 1982; 11:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luciano AY, Jinnah HA, Pfeiffer RF, et al. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 2014; 20:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           An JY, Kim JS, Kim YI, Lee KS. Successful treatment of the Meige syndrome with oral zolpidem monotherapy. Mov Disord 2008; 23:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park IS, Kim JS, An JY, et al. Excellent response to oral zolpidem in a sporadic case of the myoclonus dystonia syndrome. Mov Disord 2009; 24:2172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garretto NS, Bueri JA, Rey RD, et al. Improvement of blepharospasm with Zolpidem. Mov Disord 2004; 19:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evidente VG. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology 2002; 58:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyazaki Y, Koizumi H, Miyamoto R, et al. Treatment of isolated dystonia with Zolpidem. Mov Disord Clin Pract 2016; 3:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badillo SPJ, Jamora RDG. Zolpidem for the treatment of dystonia. Front Neurol 2019; 10:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope 2017; 127:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonyan K, Frucht SJ, Blitzer A, et al. A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity. Sci Rep 2018; 8:16111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005; 20:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang AE. Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Adv Neurol 1988; 50:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999; 14:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parr JR, Green AL, Joint C, et al. Deep brain stimulation in childhood: An effective treatment for early onset idiopathic generalised dystonia. Arch Dis Child 2007; 92:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alterman RL, Miravite J, Weisz D, et al. Sixty hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007; 69:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007; 130:2879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alterman RL, Snyder BJ. Deep brain stimulation for torsion dystonia. Acta Neurochir Suppl 2007; 97:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: A prospective 3 year follow-up study. Lancet Neurol 2007; 6:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox MD, Alterman RL. Brain stimulation for torsion dystonia. JAMA Neurol 2015; 72:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moro E, LeReun C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: A systematic review and meta-analysis. Eur J Neurol 2017; 24:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues FB, Duarte GS, Prescott D, et al. Deep brain stimulation for dystonia. Cochrane Database Syst Rev 2019; 1:CD012405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brüggemann N, Domingo A, Rasche D, et al. Association of pallidal neurostimulation and outcome predictors with X-linked dystonia parkinsonism. JAMA Neurol 2019; 76:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanger TD. Deep brain stimulation for cerebral palsy: Where are we now? Dev Med Child Neurol 2020; 62:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355:1978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012; 11:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaias IU, Alterman RL, Tagliati M. Deep brain stimulation for primary generalized dystonia: Long-term outcomes. Arch Neurol 2009; 66:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cif L, Vasques X, Gonzalez V, et al. Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: An open-label study. Mov Disord 2010; 25:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reese R, Gruber D, Schoenecker T, et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord 2011; 26:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: Blinded evidence of benefit beyond 5 years. Brain 2013; 136:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Artusi CA, Dwivedi A, Romagnolo A, et al. Differential response to pallidal deep brain stimulation among monogenic dystonias: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2020; 91:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alterman RL, Filippidis AS. Genetic Subtypes and Deep Brain Stimulation in Dystonia. Mov Disord Clin Pract 2018; 5:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarva H, Trosch R, Kiss ZHT, et al. Deep brain stimulation in isolated dystonia with a GNAL mutation. Mov Disord 2019; 34:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starr PA, Turner RS, Rau G, et al. Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: Techniques, electrode locations, and outcomes. J Neurosurg 2006; 104:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vayssiere N, van der Gaag N, Cif L, et al. Deep brain stimulation for dystonia confirming a somatotopic organization in the globus pallidus internus. J Neurosurg 2004; 101:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman BD, Starr PA, Marks WJ Jr, Ostrem JL. Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. Stereotact Funct Neurosurg 2009; 87:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zauber SE, Watson N, Comella CL, et al. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. J Neurosurg 2009; 110:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blahak C, Capelle HH, Baezner H, et al. Micrographia induced by pallidal DBS for segmental dystonia: A subtle sign of hypokinesia? J Neural Transm (Vienna) 2011; 118:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrader C, Capelle HH, Kinfe TM, et al. GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia. Neurology 2011; 77:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahlknecht P, Georgiev D, Akram H, et al. Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation. Brain 2018; 141:3023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun B, Chen S, Zhan S, et al. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl 2007; 97:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleiner-Fisman G, Liang GS, Moberg PJ, et al. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: Impact on severity, neuropsychological status, and quality of life. J Neurosurg 2007; 107:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011; 76:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schjerling L, Hjermind LE, Jespersen B, et al. A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia. J Neurosurg 2013; 119:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hock AN, Jensen SR, Svaerke KW, et al. A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 years. Parkinsonism Relat Disord 2022; 96:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgartner AJ, Thompson JA, Kern DS, Ojemann SG. Novel targets in deep brain stimulation for movement disorders. Neurosurg Rev 2022; 45:2593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pretto TE, Dalvi A, Kang UJ, Penn RD. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008; 109:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eltahawy HA, Saint-Cyr J, Giladi N, et al. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: Outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 2004; 54:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschländer A, Asmus F, Gasser T, et al. Sporadic rapid-onset dystonia-parkinsonism syndrome: Failure of bilateral pallidal stimulation. Mov Disord 2005; 20:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005; 57:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang JG, Zhang K, Wang ZC, et al. Deep brain stimulation in the treatment of secondary dystonia. Chin Med J (Engl) 2006; 119:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: A meta-analysis. Mov Disord 2013; 28:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horisawa S, Yamaguchi T, Abe K, et al. A single case of MRI-guided focused ultrasound ventro-oral thalamotomy for musician's dystonia. J Neurosurg 2018; 131:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horisawa S, Yamaguchi T, Abe K, et al. Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study. Mov Disord 2021; 36:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 2005; 25:10502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberley TJ, Borich MR, Arora S, Siebner HR. Multiple sessions of low-frequency repetitive transcranial magnetic stimulation in focal hand dystonia: Clinical and physiological effects. Restor Neurol Neurosci 2013; 31:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pirio Richardson S, Tinaz S, Chen R. Repetitive transcranial magnetic stimulation in cervical dystonia: Effect of site and repetition in a randomized pilot trial. PLoS One 2015; 10:e0124937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latorre A, Rocchi L, Berardelli A, et al. The use of transcranial magnetic stimulation as a treatment for movement disorders: A critical review. Mov Disord 2019; 34:769.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4887 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7908789" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dopa-responsive dystonia: pathological and biochemical observations in a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11405805" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Response to levodopa treatment in dopa-responsive dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11472874" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The long-term response to levodopa in dopa-responsive dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16722965" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24018121" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3400509" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12791196" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Torsion Dystonia in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30707939" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6858772" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Double-blind evaluation of trihexyphenidyl in dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6136938" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High dosage anticholinergic therapy in dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3511401" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6363970" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cranial dystonia: double-blind crossover study of anticholinergics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1516073" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Baclofen in the treatment of dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35253510" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Status Dystonicus in Children: A Cross-Sectional Study and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34840878" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pediatric Dystonic Storm: A Hospital-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205970" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Terminology for preparations of botulinum neurotoxins: what a difference a name makes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17825685" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22405829" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29230798" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Botulinum toxin type A therapy for cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27176573" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Botulinum toxin type B for cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27782297" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852744" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Botulinum toxin type A versus anticholinergics for cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18458230" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164716" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25432724" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diagnosis and treatment of dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29653859" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21520284" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185301" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33346814" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2041443" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31477348" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31937363" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11372922" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22359151" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18546321" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23779062" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25595221" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20359934" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30837195" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620852" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22932474" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30464031" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26467676" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Neutralizing Antibody and Botulinum Toxin Therapy:   A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31897089" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32249176" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Patient-reported responses to medical treatment in primary dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20482602" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : EFNS guidelines on diagnosis and treatment of primary dystonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6460467" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133512" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040721" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-term effects of tetrabenazine in hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25406829" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of myoclonus-dystonia syndrome with tetrabenazine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18581473" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Successful treatment of the Meige syndrome with oral zolpidem monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19735067" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Excellent response to oral zolpidem in a sporadic case of the myoclonus dystonia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15300667" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Improvement of blepharospasm with Zolpidem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865155" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30713923" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of Isolated Dystonia with Zolpidem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31379728" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Zolpidem for the Treatment of Dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27808415" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : An open-label study of sodium oxybate in Spasmodic dysphonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30382161" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15986420" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3041761" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Dopamine agonists and antagonists in the treatment of idiopathic dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10435503" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : An open trial of clozapine for dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16928997" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460025" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Deep brain stimulation in childhood: an effective treatment for early onset idiopathic generalised dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17698790" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Sixty hertz pallidal deep brain stimulation for primary torsion dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17905796" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The Canadian multicentre study of deep brain stimulation for cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17691304" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Deep brain stimulation for torsion dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17303528" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25894231" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Brain Stimulation for Torsion Dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28186378" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30629283" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Deep brain stimulation for dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30508028" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31211420" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Deep brain stimulation for cerebral palsy: where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17093249" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pallidal deep-brain stimulation in primary generalized or segmental dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23123071" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364931" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Deep brain stimulation for primary generalized dystonia: long-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20063427" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: an open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21312284" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23423670" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32079672" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30838292" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Genetic Subtypes and Deep Brain Stimulation in Dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30536916" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Deep Brain Stimulation in Isolated Dystonia With a GNAL Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16619651" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15309906" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Deep brain stimulation for dystonia confirming a somatotopic organization in the globus pallidus internus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19174619" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976055" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21246224" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Micrographia induced by pallidal DBS for segmental dystonia: a subtle sign of hypokinesia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775741" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30165511" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17691306" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Subthalamic nucleus stimulation for primary dystonia and tardive dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17639870" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21383323" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Subthalamic nucleus deep brain stimulation in primary cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24116723" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35245879" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35511309" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Novel targets in deep brain stimulation for movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759568" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028135" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15455448" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Sporadic rapid-onset dystonia-parkinsonism syndrome: failure of bilateral pallidal stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15852393" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pallidal stimulation improves pantothenate kinase-associated neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17199958" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Deep brain stimulation in the treatment of secondary dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23408442" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30239322" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A single case of MRI-guided focused ultrasound ventro-oral thalamotomy for musician's dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34050695" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16280588" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23340117" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Multiple sessions of low-frequency repetitive transcranial magnetic stimulation in focal hand dystonia: clinical and physiological effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25923718" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Repetitive transcranial magnetic stimulation in cervical dystonia: effect of site and repetition in a randomized pilot trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31034682" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The use of transcranial magnetic stimulation as a treatment for movement disorders: A critical review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
